25 results
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
24 Oct 19
62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence
8:36am
% of Patients Achieving or Maintaining Transfusion Independence
Data Support RARA as the Optimal Predictive Biomarker for Patient Selection
CAMBRIDGE, Mass … study the combination in more patients, we are also seeing a high rate of transfusion independence and early evidence of durable responses. We
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
trial of SY-1425 and azacitidine Primary Objective: ORR per IWG Other Analyses: Composite CR rate Duration of response Transfusion independence Overall … /CRi Rate 67% Transfusion independence 67% ORR
New translational data highlight potential of SY-1425 to benefit ND unfit AML patients who may
8-K
EX-99.2
1baj3mtcmnru q0r
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-99.1
v30x6x9edw50q4zv
26 May 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
kpmg70xdfzo40e
25 Feb 21
Regulation FD Disclosure
7:01am
PRE 14A
c8kcxurxg6m5ctr
12 Apr 24
Preliminary proxy
4:30pm
8-K
EX-99.1
60aunqji6ku279k
8 Jan 24
Regulation FD Disclosure
7:06am
8-K
EX-99.1
2mfdjgm
2 Dec 19
Regulation FD Disclosure
7:03am
8-K
EX-99.1
trtdv7713m
13 Jan 20
Regulation FD Disclosure
6:11am
8-K
EX-99.1
kdvul3248 s64
25 May 23
Regulation FD Disclosure
5:10pm
10-K
uq7idjcwrsy1w7 gkkfn
20 Mar 17
Annual report
12:00am